Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Birth defects prevention bill awaits President's signature after House passage March 10.

This article was originally published in The Tan Sheet

Executive Summary

FOLIC ACID AWARENESS, RESEARCH PROGRAMS WOULD RECEIVE FUNDING BOOST under a birth defects prevention bill passed by the House in a 405-2 vote March 10. The Birth Defects Prevention Act (S 419), introduced last March by Sen. Kit Bond (R-Mo.), is companion legislation to a House measure sponsored by Rep. Solomon Ortiz (D-Tex.). The House passed the bill under a suspension of rules, thereby prohibiting the introduction of any floor amendments; S 419 cleared the Senate via voice vote on June 12 ("The Tan Sheet" June 23, 1997, In Brief). The bill now awaits the President's signature.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel